Physician profile
Robert M Wheeler
NPI 1851368831
$5,357.20
in general payments reported to CMS, 2019-2025
36 companies · $474 in 2025
The $474 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $237 · 2021: $743 · 2022: $1,532 · 2023: $1,213 · 2024: $703 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.07 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $911.67 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Fujirebio Diagnostics, Incorporated | $724.94 | 2022 | |
| Astellas Pharma US INC | $450.92 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $359.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $283.57 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Shield Therapeutics INC | $278.62 | 2023-2025 | Accrufer |
| Amgen INC. | $246.22 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $235.32 | 2022-2025 | |
| Exeltis, USA INC. | $233.39 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $222.88 | 2021-2022 | |
| Lupin INC. | $197.25 | 2019-2021 | |
| Avion Pharmaceuticals | $171.21 | 2020-2023 | Balcoltra |
| Coopersurgical, INC. | $149.43 | 2021 | |
| Myriad Women'S Health, INC. | $118.12 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $113.03 | 2023-2025 | Myfembree, Gemtesa |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $88.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $77.22 | 2019-2024 | Bridion, Vaxneuvance, Gardasil 9 |
| Hologic Sales and Service, LLC | $56.46 | 2025 | Myosure Tissue Removal Device, Novasure, Thinprep 2000 Processor |
| Myovant Sciences INC. | $41.72 | 2021-2022 | |
| Solventum Corporation | $39.25 | 2024 | Prevena |
| Evofem Biosciences, INC. | $35.03 | 2021-2023 | Phexxi |
| Organon LLC | $33.98 | 2023-2024 | Nexplanon |
| Novo Nordisk INC | $32.21 | 2022-2023 | Wegovy |
| Therapeuticsmd, INC. | $29.65 | 2021-2022 | |
| Allergan, INC. | $28.88 | 2019 | |
| Avanos Medical | $24.21 | 2023 | Quikbloc |
| Urovant Sciences INC | $23.55 | 2022 | |
| Baxter Healthcare | $23.45 | 2022 | |
| Trevena, INC. | $22.86 | 2021 | |
| Axonics, INC. | $19.51 | 2023 | Axonics |
| Becton, Dickinson and Company | $18.06 | 2021 | |
| Ethicon US, LLC | $15.17 | 2025 | Vistaseal, Stratafix, Dermabond Prineo |
| Ascend Therapeutics US, LLC | $14.50 | 2023 | |
| Sage Therapeutics, LLC | $13.71 | 2025 | Zurzuvae |
| Acessa Health INC. | $12.57 | 2019 | |
| Duchesnay USA Incorporated | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.